GLP-1 vs. GLP-2 vs. GLP-3: What’s the Difference? (2026 Research Guide)
The terms GLP-1, GLP-2, and GLP-3 appear across research literature, clinical trial databases, and peptide vendor catalogs — but they refer to fundamentally different compounds with different receptors, different mechanisms, and entirely different research applications. This guide breaks down each one clearly so researchers can understand what they’re actually working with.
GLP-1: The Benchmark Incretin
GLP-1 (glucagon-like peptide-1) is an endogenous incretin hormone secreted by intestinal L-cells in response to food intake. Native GLP-1 has a plasma half-life of just 1–2 minutes due to rapid degradation by the enzyme DPP-4. The research compound known as semaglutide (CAS 910463-68-2) is a GLP-1 analog with 94% sequence homology to native GLP-1, extended to a ~7-day half-life via a C18 fatty diacid albumin-binding chain.
GLP-1 receptor (GLP-1R) activation produces: glucose-dependent insulin secretion from pancreatic beta cells; glucagon suppression from alpha cells; delayed gastric emptying; and central satiety signaling via the hypothalamic arcuate nucleus and nucleus tractus solitarius. Semaglutide is the active compound in FDA-approved Ozempic (type 2 diabetes) and Wegovy (chronic weight management), making GLP-1R agonism the most clinically validated mechanism in this compound class.
GLP-2: The Intestinotrophic Hormone
GLP-2 (glucagon-like peptide-2) is co-secreted with GLP-1 by intestinal L-cells but acts on a completely different receptor — the GLP-2 receptor (GLP-2R), which is expressed primarily in the gut, not in the pancreas or hypothalamus. GLP-2’s primary research applications center on intestinal and gut mucosal biology: it promotes enterocyte proliferation, inhibits apoptosis, increases intestinal villus height, strengthens the gut barrier, and enhances nutrient absorption.
The FDA-approved GLP-2 analog teduglutide (Gattex/Revestive) is approved for short bowel syndrome — a condition where GLP-2’s intestinotrophic effects directly compensate for reduced absorptive surface area. This gives GLP-2 research a clear mechanistic rationale distinct from metabolic weight-loss research. Research-grade GLP-2 (CAS 106612-94-6) enables investigation of gut barrier function, intestinal regeneration, and mucosal biology in ways that GLP-1R agonists cannot.
GLP-3: The Triple-Agonist Research Frontier
GLP-3 is the informal designation for retatrutide (LY-3437943, CAS 2381089-83-2) — an acylated peptide that simultaneously activates GLP-1R, the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GCGR). The “GLP-3” label reflects its position as the third-generation evolution of GLP research: from single-agonist (GLP-1R only, as in semaglutide) to dual-agonist (GLP-1R + GIPR, as in tirzepatide) to triple-agonist (GLP-1R + GIPR + GCGR).
The addition of GCGR activation is what makes GLP-3/retatrutide mechanistically distinct. Glucagon receptor stimulation drives hepatic fatty acid oxidation, increases energy expenditure, and promotes a catabolic metabolic state — complementing the anabolic insulin-sensitizing and appetite-suppressing effects of GLP-1R and GIPR co-activation. Phase 2 trial data showed approximately 24% mean body weight reduction at 48 weeks at the highest dose — outcomes exceeding tirzepatide and semaglutide in timeline comparisons.
Side-by-Side Comparison
| Feature | GLP-1 (Semaglutide) | GLP-2 (Research Peptide) | GLP-3 (Retatrutide) |
|---|---|---|---|
| CAS Number | 910463-68-2 | 106612-94-6 | 2381089-83-2 |
| Target Receptor(s) | GLP-1R | GLP-2R | GLP-1R + GIPR + GCGR |
| Mechanism Focus | Insulin secretion, satiety, gastric emptying | Intestinal growth, gut barrier, mucosal repair | Metabolic energy balance, fat oxidation, satiety |
| Primary Research Area | Metabolic, cardiovascular | Gut biology, intestinal research | Metabolic, obesity, MASH |
| Half-Life | ~7 days | Native: ~7 min; research analog: longer | ~6 days |
| FDA-Approved Analog | Ozempic, Wegovy | Teduglutide (Gattex) | None (Phase 3) |
| Regulatory Status | Research peptide (Ozempic is Rx) | Research peptide (Gattex is Rx) | Research only |
Why the Distinction Matters for Researchers
These three compounds are not interchangeable or on a linear spectrum of potency. GLP-1 and GLP-3 share the GLP-1R target but differ in the number of additional receptors engaged. GLP-2 shares no receptors with GLP-1 or GLP-3 — it is a completely different research tool for a completely different biological question. Combining GLP-1 or GLP-3 with a gut-biology protocol using GLP-2 is mechanistically complementary, not redundant.
Frequently Asked Questions
Are GLP-1, GLP-2, and GLP-3 from the same gene?
GLP-1 and GLP-2 are both derived from the proglucagon gene (GCG) through tissue-specific post-translational processing. GLP-3 (retatrutide) is a synthetic construct — not a naturally occurring proglucagon fragment — engineered to target three receptors simultaneously.
Can GLP-1 and GLP-2 be used in research together?
They target completely different receptors and tissues, making them complementary research tools. GLP-1R agonists affect pancreatic, hypothalamic, and cardiovascular biology; GLP-2R agonists affect intestinal epithelium and gut barrier integrity.
Which GLP compound is most advanced in clinical development?
GLP-1 agonists (semaglutide, liraglutide) are FDA-approved. GLP-2 analogs (teduglutide) are FDA-approved for SBS. GLP-3/retatrutide is in Phase 3 — the most clinically advanced unapproved compound in this class.
→ GLP-1 (Semaglutide) Research Peptide | GLP-2 Research Peptide | GLP-3 (Retatrutide) Research Peptide
